Product/Composition:- | Daclatasvir |
---|---|
Strength:- | 30 mg, 60 mg |
Form:- | Tablet |
Reference Brands:- | Daklinza® (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Daclatasvir is an effective oral antiviral used to treat chronic Hepatitis C infection by inhibiting the NS5A protein critical for viral replication. Available as 30 mg and 60 mg tablets, it is manufactured under EU-GMP and USFDA standards. Widely used in combination therapies, Daclatasvir supports broad HCV genotype coverage. Ideal for B2B supply, hospital tenders, and licensing, it comes with comprehensive regulatory dossiers enabling quick registration in global markets.
Daclatasvir is a potent direct-acting antiviral (DAA) used in the treatment of chronic Hepatitis C virus (HCV) infection. It functions by selectively inhibiting the NS5A protein, a key factor in viral replication and assembly. Available as oral tablets in strengths of 30 mg and 60 mg, Daclatasvir is commonly used in combination with Sofosbuvir or other antivirals for broad genotype coverage. Manufactured under strict EU-GMP and USFDA standards, it is suitable for B2B supply, hospital tenders, and licensing. Comprehensive regulatory dossiers support fast market registration and global distribution.